key: cord-0790081-80gcr0ci
authors: Sharma, Amit Raj; Batra, Gitika; Kumar, Mukesh; Mishra, Abhishek; Singla, Rubal; Singh, Ashutosh; Singh, Rahul Soloman; Medhi, Bikash
title: BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic
date: 2020-07-03
journal: Allergol Immunopathol (Madr)
DOI: 10.1016/j.aller.2020.05.002
sha: 8bddf74924dc4da1cf56b40a5c190e20a22997b0
doc_id: 790081
cord_uid: 80gcr0ci

Abstract The impact of COVID-19 is changing country wise and depends on universal immunization policies. COVID-19 badly affects countries that did not have universal immunization policies or having them only for the selective population of countries (highly prominent population) like Italy, USA, UK, Netherland, etc. Universal immunization of BCG can provide great protection against the COVID-19 infection because the BCG vaccine gives broad protection against respiratory infections. BCG vaccine induces expressions of the gene that are involved in the antiviral innate immune response against viral infections with long-term maintenance of BCG vaccine-induced cellular immunity. COVID-19 cases are reported very much less in the countries with universal BCG vaccination policies such as India, Afghanistan, Nepal, Bhutan, Bangladesh, Israel, Japan, etc. as compared to without BCG implemented countries such as the USA, Italy, Spain, Canada, UK, etc. BCG vaccine provides protection for 50 to 60 years of immunization, so the elderly population needs to be revaccinated with BCG. Several countries started clinical trials of the BCG vaccine for health care workers and elderly people. BCG can be uses as a prophylactic treatment until the availability of the COVID-19 vaccine.

The recent COVID-19 outbreak from Wuhan city in China and spread globally with 4648479 confirmed cases and 309008 deaths (as of May 16, 2020). 1 SARS-CoV2 is pathogenically stronger than the previous outbreaks of coronavirus (Middle East Respiratory Syndrome (MERS) and

Severe Acute Respiratory Syndrome (SARS)). 2 SARS-CoV2 is transmitted from one person to another during sneezing or coughing droplets, reported in family settings as well as hospitals 3 and is also transmitted from contaminated surfaces or contaminated consumables by self-inoculation through the eyes, mouth and nose. [4] [5] SARS-Cov-2 is closely related to the previous SARS coronavirus and the origin of SARS-Cov-2 is from the same reservoir bat host. 6 9 Current data is emphasizing that the available vaccines prevent viral infections by activation of the antiviral immune response, such as BCG. According to the literature available, BCG activates the human immune system against several types of viruses such as human Respiratory Syncytial Virus (hRSV), and human papillomavirus (HPV). 10 This review deals with the importance of BCG in the prevention of COVID-19 expansion and its severity. Literature and surveys exhibiting the COVID-19 spread and severity are much greater in those countries which did not have any BCG vaccination regimen. Different countries implemented differing policies for BCG immunization because of their undefined efficacy. 11 Various countries, such as India, Japan, etc., are having a universal BCG immunization program, whereas other countries such as Canada, USA, Italy, Spain, etc.

implemented for the high-risk community. BCG immunization procedures differ from one country to another in favor of age, administration route, and doses of the vaccine. Most of the countries previously used three booster doses of BCG vaccine but nowadays only a single dose is used by J o u r n a l P r e -p r o o f an intradermal route at an early age, around the first year of life in newborns. 12 No scientific evidence is available for booster doses or revaccination of BCG 13 so the World Health Organization (WHO) Global Programme on Tuberculosis and Vaccines in 1995 did not recommend repeat BCG schemes. The WHO recommends that one dose of the BCG vaccine should be administered in all neonates of countries with a high incidence of TB. 14 Immunization policies are revised or changed country-wise from time to time, depending on health policies, variation in evidence, community perception, the difference in TB, and comorbid incidence (HIV). 11 The meta-analysis found the variation in BCG vaccine efficacy reduced the TB risk by 50% in controlled trials and the duration of the vaccine susceptibility remains unknown. [15] [16] One study reported that the TB mortality attributed to vaccination in a 20-year BCG and placebocontrolled trial fell by 82%. [17] [18] In that clinical trial, vaccination started from 1935 to 1938, and prospective TB cases finding by 1947. 18 Another controlled trial stated the efficacy of the BCG vaccine with long term protection, approximately 60 years of age after vaccination. 19

BCG vaccination provides a wide range of safety against bacterial and viral infections but there is no evidence regarding BCG, whether it directly reduced the COVID-19 infection or not. 10 A study has shown the correlation between BCG vaccination and COVID-19 infection, and studies have also shown fewer COVID-19 cases in universally implemented countries. The universal use of the BCG vaccine for the community can decrease the spread of COVID-19, and it can help to stop the transmission of the disease. 20 Randomized controlled trials are needed to determine the role of BCG vaccination in immune activation against COVID-19. Nevertheless, BCG has shown a number of side effects (blood in urine, joint pain, nausea, vomiting, painful urination, etc.) in immune-compromised people and pregnant women. 21 The BCG vaccine may boost the immune system's ability to fight off pathogens, including the deadly coronavirus. Various investigations showed that the BCG vaccine also defends against viral infections affecting the respiratory tract in humans and mice. BCG protects against bacterial infection and also protects against respiratory viral infections. 10, 22 In this study, mice who have BCG vaccination before infection have low Influenza A load in their blood with less damage to the lungs. 23-24 Several studies have stated that the BCG vaccine stimulates the resistance against viral infection in animals by inducing the epigenetic modifications in macrophages, monocytes, dendritic cells, and other immune cells.

These immune cells enhance the production of pro-inflammatory cytokines such as INF-γ, TNFα, and IL-1b, and develop the resistance for herpes type 1 and 2 viruses. 24-25 These studies provide an idea that BCG vaccination can activate the immune system against viral infection. Thus, there is a path by which vaccine provides protection and reduces the risk of severely infectious diseases.

Further studies also revealed that the BCG vaccine increases resistance in laboratory animals against other viruses, and ensure that it can be uses as a method of COVID-19 treatment. COVID-19 spread extensively in those countries which did not implement BCG vaccination, such as the USA, Italy, Spain, France, Germany, South Korea, Iran, etc. whereas those countries that have implemented BCG vaccination earlier showed a slower spread and low severity of COVID-19. Antiviral innate immune activation depends on the particular type of TLR signaling mechanism that is stimulated through the particular type of pathogen. [36] [37] [38] [39] [40] Studies have shown that BCG expressed different proteins that activate TLRs and activate macrophages and dendritic cells. After the activation of these cells, they produce pro-inflammatory cytokines. 41 DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) is a C-type lectin that interacts with bacterial wall constituents, and helps to recognize and internalize the process of BCG. 42 Dendritic cells get activated after interactions with the pathogen and initiate dendritic cell migration and maturation, which is described by the upregulation of CD40, CD80, CD83, and CD86 costimulatory molecules. 43 Antigen 85 expresses on the M.TB surface also present on the BCG surface, which induced the secretion of tumor necrosis factor (TNF-α), interleukin-6 (IL-6), and, interleukin-1beta (IL-1β) 44-45. It can activate immune system cells by generating pro-inflammatory cytokines. 43 Adaptive immune response initiates by antigen presentation when an antigenpresenting cell presents an antigen peptide with major histocompatible complex (MHC) molecules to naive T cells, found spleen to be the most affected organ or any secondary lymphoid tissues. 46 In vitro and in vivo studies have reported that the skin dendritic cells having BCG inside migrate to the lymph nodes and activate both types of T cells CD4 + and CD8 + T cells by the secretion of TNF-α, IL-6, and IL-12. [47] [48] [49] [50] Surprisingly, it has been stated that the stimulation of antigen-specific T cell responses by the BCG infected dendritic cells is induced by infected neutrophils. 51

After BCG vaccination, adaptive immune system cells (CD4 + and CD8 + T cells) become activated, initiate the immune response against the BCG antigens 46, 52 and increase the secretion of IFN-γ.

IFN-γ improves the potential against mycobacteria of the macrophages [45] [46] , and it also activates against viruses. IFN-γ, the specific cell type of cytokine that involved in B cells activation and differentiation, B-cells differentiated into plasma B cells, and memory B cells where plasma B cells produced antibodies against the particular antigen. Activated CD8 + T cells proliferate into specific CD8 + T cells against BCG antigen and persist for ten weeks in peripheral blood. 53 Specific CD8 + T cells against an antigen released IFN-γ, and also express the perforins and granzymes to the cytotoxic activity of CD8 + T cells. 53-54 CD4 + and CD8 + T cells specific for BCG antigen 

Revaccination of BCG did not provide any extra protection against TB. 13 Control and prevention of tuberculosis provided guidelines that people who work in hospital settings regardless of age, those unvaccinated earlier, and those having Heaf grade 1 or negative on tuberculin testing, should be vaccinated for the BCG vaccine. The HCW were directly dealing with TB patients and did not have a BCG scar so revaccination should be recommended. 57-58 The BCG vaccine causes swelling at the site of vaccination. However, cross-reactions of BCG may occur in people with a compromised immune system and pregnant women, so extra protection should be provided to pregnant women and immune-compromised people before BCG vaccination. 59 A study has shown that after revaccination in students, the relative risk of adverse reactions with the scar was twice, as compared to without scar. 60 The researchers reported that the second dose of BCG or revaccination did not generally cause any adverse reactions -sometimes it can cause adverse reactions but these are very rare. The study reporting in American Indians and Alaskan natives BCG vaccination provided that the long-lasting potency and it has shown that a dose of BCG provides safety for 50 to 60 years. 61 The clinical trials also observed the same efficacy of the BCG vaccine in observational case-control studies, but unknown in the elderly population. 60 Another Table 1 SARS-CoV-2 infection in BCG implemented countries: Table 2 The average of the total number of COVID-19 cases is 44723 in without BCG implemented countries, whereas implemented countries have a very much lower average of infected cases 11940.98. BCG implemented countries have fewer deaths percentage, around 5.08%, as compared to the 11% in without implemented countries. Moreover, the recovered cases percentage is also high in BCG implemented countries, at around 43%, whereas without implemented countries it is 35%.

The The correlation of BCG vaccination with COVID-19 has shown fewer confirmed cases with low mortality and a high recovered rate in universal BCG immunization countries. Table 1 contains the data of BCG unimplemented countries, and Table 2 pandemic.

The authors declare that they have no conflict of interest.

None. 

COVID-19 coronavirus pandemic

SARS and MERS: recent insights into emerging coronaviruses

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination

Severe acute respiratory syndrome coronavirus on hospital surfaces

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Structural insights into coronavirus entry

Non-specific effects of BCG vaccine on viral infections. Clinical Microbiology and Infection

The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS medicine

BCG immunization: review of past experience, current use, and future prospects. Current clinical topics in infectious diseases

BCG vaccine: efficacy and indications for vaccination and revaccination

Global tuberculosis control: surveillance, planning, financing

Efficacy of BCG vaccine in the prevention of tuberculosis

Rotavirus NSP4 triggers secretion of proinflammatory cytokines from macrophages via Toll-like receptor 2

Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus

Reading the viral signature by Toll-like receptors and other pattern recognition receptors

Bacterial protein toll-like-receptor agonists: a novel perspective on vaccine adjuvants

Mycobacterium bovis Bacillus Calmette-Guérin infects DC-SIGN-dendritic cell and causes the inhibition of IL-12 and the enhancement of IL-10 production

Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors

Mycobacterial growth inhibition is associated with trained innate immunity

Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis

Tuberculosis vaccines: time to think about the next generation

BCG skin infection triggers IL-1R-MyD88

BCG re-vaccination

BCG vaccine: efficacy and indications for vaccination and revaccination

Tuberculin skin test conversion among medical students at a teaching hospital in Rio de Janeiro, Brazil. Infection Control & Hospital Epidemiology

Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a metaanalysis of the literature

Influence of advanced age on Mycobacterium bovis BCG vaccination in guinea pigs aerogenically infected with Mycobacterium tuberculosis